{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:29:26Z","timestamp":1794360566215,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004270","name":"Royal Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Molecular components in blood, such as proteins, are used as biomarkers to detect or predict disease states, guide clinical interventions and aid in the development of therapies. While multiplexing proteomics methods promote discovery of such biomarkers, their translation to clinical use is difficult due to the lack of substantial evidence regarding their reliability as quantifiable indicators of disease state or outcome. To overcome this challenge, a novel orthogonal strategy was developed and used to assess the reliability of biomarkers and analytically corroborate already identified serum biomarkers for Duchenne muscular dystrophy (DMD). DMD is a monogenic incurable disease characterized by progressive muscle damage that currently lacks reliable and specific disease monitoring tools.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two technological platforms are used to detect and quantify the biomarkers in 72 longitudinally collected serum samples from DMD patients at 3 to 5 timepoints. Quantification of the biomarkers is achieved by detection of the same biomarker fragment either through interaction with validated antibodies in immuno-assays or through quantification of peptides by Parallel Reaction Monitoring Mass Spectrometry assay (PRM-MS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five, out of ten biomarkers previously identified by affinity-based proteomics methods, were confirmed to be associated with DMD using the mass spectrometry-based method. Two biomarkers, carbonic anhydrase III and lactate dehydrogenase B, were quantified with two independent methods, sandwich immunoassays and PRM-MS, with Pearson correlations of 0.92 and 0.946 respectively. The median concentrations of CA3 and LDHB in DMD patients was elevated in comparison to those in healthy individuals by 35- and 3-fold, respectively. Levels of CA3 vary between 10.26 and 0.36 ng\/ml in DMD patients whereas those of LDHB vary between 15.1 and 0.8 ng\/ml.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results demonstrate that orthogonal assays can be used to assess the analytical reliability of biomarker quantification assays, providing a means to facilitate the translation of biomarkers to clinical practice. This strategy also warrants the development of the most relevant biomarkers, markers that can be reliably quantified with different proteomics methods.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12014-023-09412-1","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:01:42Z","timestamp":1686542502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers"],"prefix":"10.1186","volume":"20","author":[{"given":"Camilla","family":"Johansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helian","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Edfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Tegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Forststr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Spitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Uhl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Al-Khalili","family":"Szigyarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"9412_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nbt1235","volume":"24","author":"N Rifai","year":"2006","unstructured":"Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971\u2013983.","journal-title":"Nat Biotechnol"},{"key":"9412_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/978-3-319-41448-5_23","volume":"919","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Brasier AR. Qualification and Verification of protein biomarker candidates. Adv Exp Med Biol. 2016;919:493\u2013514.","journal-title":"Adv Exp Med Biol"},{"key":"9412_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14789450.2019.1559062","volume":"16","author":"VA Hristova","year":"2019","unstructured":"Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019;16:93.","journal-title":"Expert Rev Proteomics"},{"key":"9412_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4155\/bio-2018-0061","volume":"10","author":"JL Allinson","year":"2018","unstructured":"Allinson JL. Clinical biomarker validation. Bioanalysis. 2018;10:957\u2013968.","journal-title":"Bioanalysis"},{"key":"9412_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","volume":"14","author":"VB Kraus","year":"2018","unstructured":"Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14:354\u2013362.","journal-title":"Nat Rev Rheumatol"},{"key":"9412_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1878-5085-4-7","volume":"4","author":"E Drucker","year":"2013","unstructured":"Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4:7.","journal-title":"EPMA J"},{"key":"9412_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/bmm-2017-0024","volume":"11","author":"A Scherer","year":"2017","unstructured":"Scherer A. Reproducibility in biomarker research and clinical development: a global challenge. Biomark Med. 2017;11:309\u2013312.","journal-title":"Biomark Med"},{"key":"9412_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19957-6","volume":"11","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Palmqvist S, Blennow K, Hansson O. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat Commun. 2020;11:1\u201311.","journal-title":"Nat Commun"},{"key":"9412_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jim.2009.06.003","volume":"347","author":"AN Hoofnagle","year":"2009","unstructured":"Hoofnagle AN, Wener MH. The fundamental flaws of Immunoassays and potential solutions using Tandem Mass Spectrometry. J Immunol Methods. 2009;347:3.","journal-title":"J Immunol Methods"},{"key":"9412_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1586\/erm.12.31","volume":"12","author":"T Pham","year":"2012","unstructured":"Pham T, Piersma SR, Oudgenoeg G, Jimenez CR. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn. 2012;12:343\u2013359.","journal-title":"Expert Rev Mol Diagn"},{"key":"9412_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-015-9102-9","volume":"13","author":"CA Crutchfield","year":"2016","unstructured":"Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteom. 2016;13:1.","journal-title":"Clin Proteom"},{"key":"9412_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/prca.201400014","volume":"8","author":"X Shen","year":"2014","unstructured":"Shen X, Young R, Canty JM, Qu J. Quantitative proteomics in cardiovascular research: global and targeted strategies. Proteom Clin Appl. 2014;8:488.","journal-title":"Proteom Clin Appl"},{"key":"9412_CR13","first-page":"1","volume":"8","author":"C Al-Khalili Szigyarto","year":"2018","unstructured":"Al-Khalili Szigyarto C, Spitali P. Biomarkers of Duchenne muscular dystrophy: current findings. Degener Neurol Neuromuscul Dis. 2018;Volume 8:1\u201313.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"9412_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393.","journal-title":"Lancet Neurol"},{"key":"9412_CR15","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20:18168\u201318184.","journal-title":"Molecules"},{"key":"9412_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","volume":"20","author":"HJA van Ruiten","year":"2016","unstructured":"van Ruiten HJA, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Straub V, et al. Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England. Eur J Paediatr Neurol. 2016;20:904\u2013909.","journal-title":"Eur J Paediatr Neurol"},{"key":"9412_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","volume":"381","author":"E Mercuri","year":"2013","unstructured":"Mercuri E, Muntoni F. Muscular dystrophies. The Lancet. 2013;381:845\u2013860.","journal-title":"The Lancet"},{"key":"9412_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM Mcdonald","year":"2013","unstructured":"Mcdonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity and minimal clinically important differences from a multicenter study. Muscle & Nerve. 2013;48:357\u2013368.","journal-title":"Muscle &amp;Nerve"},{"key":"9412_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/mus.21808","volume":"42","author":"CM Mcdonald","year":"2010","unstructured":"Mcdonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, et al. The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations. Muscle Nerve. 2010;42:966\u2013974.","journal-title":"Muscle Nerve"},{"key":"9412_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nmd.2014.09.015","volume":"25","author":"R de Sanctis","year":"2015","unstructured":"de Sanctis R, Pane M, Sivo S, Ricotti V, Baranello G, Frosini S, et al. Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25:14\u201318.","journal-title":"Neuromuscul Disord"},{"key":"9412_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1469-7793.2000.00243.x","volume":"529","author":"C Malm","year":"2000","unstructured":"Malm C, Nyberg P, Engstr\u00f6m M, Sj\u00f6din B, Lenkei R, Ekblom B, et al. Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. J Physiol. 2000;529:243\u2013262.","journal-title":"J Physiol"},{"key":"9412_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/14756366.2012.700640","volume":"28","author":"AK Harju","year":"2013","unstructured":"Harju AK, Bootorabi F, Kuuslahti M, Supuran CT, Parkkila S. Carbonic anhydrase III: a neglected isozyme is stepping into the limelight. J Enzyme Inhib Med Chem. 2013;28:231\u2013239.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"9412_CR23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","volume":"15","author":"V Straub","year":"2016","unstructured":"Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, de Luca A, et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 2016;15:882\u201390.","journal-title":"Lancet Neurol"},{"key":"9412_CR24","doi-asserted-by":"crossref","unstructured":"Ricotti V, Evans MRB, Sinclair CDJ, Butler JW, Ridout DA, Hogrel JY et al. Upper limb evaluation in Duchenne muscular dystrophy: Fat-water quantification by MRI, muscle force and function define endpoints for clinical trials. PLoS ONE. 2016;11:e0162542.","DOI":"10.1371\/journal.pone.0162542"},{"key":"9412_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/mus.26497","volume":"60","author":"DG Leung","year":"2019","unstructured":"Leung DG. Advancements in magnetic resonance imaging-based biomarkers for muscular dystrophy. Muscle Nerve. 2019;60:347.","journal-title":"Muscle Nerve"},{"key":"9412_CR26","doi-asserted-by":"publisher","first-page":"E1386","DOI":"10.1212\/WNL.0000000000008939","volume":"94","author":"KJ Naarding","year":"2020","unstructured":"Naarding KJ, Reyngoudt H, van Zwet EW, Hooijmans MT, Tian C, Rybalsky I, et al. MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. Neurology. 2020;94:E1386\u20131394.","journal-title":"Neurology"},{"key":"9412_CR27","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1212\/WNL.0000000000009012","volume":"94","author":"AM Barnard","year":"2020","unstructured":"Barnard AM, Willcocks RJ, Triplett WT, Forbes SC, Daniels MJ, Chakraborty S, et al. MR biomarkers predict clinical function in Duchenne muscular dystrophy. Neurology. 2020;94:e897\u2013909.","journal-title":"Neurology"},{"key":"9412_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.nmd.2019.08.011","volume":"29","author":"JW Chardon","year":"2019","unstructured":"Chardon JW, D\u00edaz-Manera J, Tasca G, B\u00f6nnemann CG, G\u00f3mez-Andr\u00e9s D, Heerschap A, et al. MYO-MRI diagnostic protocols in genetic myopathies. Neuromuscul Disord. 2019;29:827\u2013841.","journal-title":"Neuromuscul Disord"},{"key":"9412_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.15252\/emmm.201303724","volume":"6","author":"B Ayoglu","year":"2014","unstructured":"Ayoglu B, Chaouch A, Lochm\u00fcller H, Politano L, Bertini E, Spitali P, et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Mol Med. 2014;6:918\u2013936.","journal-title":"EMBO Mol Med"},{"key":"9412_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-016-9109-x","volume":"13","author":"Y Hathout","year":"2016","unstructured":"Hathout Y, Seol H, Han MHJ, Zhang A, Brown KJ, Hoffman EP. Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteom. 2016;13:1\u20139.","journal-title":"Clin Proteom"},{"key":"9412_CR31","doi-asserted-by":"crossref","unstructured":"Hathout Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet. 2014;1\u201312.","DOI":"10.1093\/hmg\/ddu366"},{"key":"9412_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.nmd.2011.05.011","volume":"21","author":"VD Nadarajah","year":"2011","unstructured":"Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochm\u00fcller H, et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord. 2011;21:569\u2013578.","journal-title":"Neuromuscul Disord"},{"key":"9412_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/prca.201300072","volume":"8","author":"F Cynthia Martin","year":"2014","unstructured":"Cynthia Martin F, Hiller M, Spitali P, Oonk S, Dalebout H, Palmblad M, et al. Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Proteom Clin Appl. 2014;8:269\u2013278.","journal-title":"Proteom Clin Appl"},{"key":"9412_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/jcsm.12304","volume":"9","author":"P Spitali","year":"2018","unstructured":"Spitali P, Hettne K, Tsonaka R, Charrout M, van den Bergen J, Koeks Z, et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. J Cachexia Sarcopenia Muscle. 2018;9:715\u2013726.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"9412_CR35","doi-asserted-by":"publisher","first-page":"104999","DOI":"10.1016\/j.phrs.2020.104999","volume":"159","author":"SC Previtali","year":"2020","unstructured":"Previtali SC, Gidaro T, D\u00edaz-Manera J, Zambon A, Carnesecchi S, Roux-Lombard P, et al. Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase ib trial in young patients with Duchenne muscular dystrophy. Pharmacol Res. 2020;159:104999.","journal-title":"Pharmacol Res"},{"key":"9412_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17982-y","volume":"7","author":"A Lourbakos","year":"2017","unstructured":"Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, et al. Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep"},{"key":"9412_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/jcsm.12517","volume":"11","author":"M Signorelli","year":"2020","unstructured":"Signorelli M, Ayoglu B, Johansson C, Lochm\u00fcller H, Straub V, Muntoni F, et al. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2020;11:505\u2013517.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"9412_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JND-190454","volume":"7","author":"K Strandberg","year":"2020","unstructured":"Strandberg K, Ayoglu B, Roos A, Reza M, Niks E, Signorelli M, et al. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. J Neuromuscul Dis. 2020;7:231\u2013246.","journal-title":"J Neuromuscul Dis"},{"key":"9412_CR39","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1021\/acs.jproteome.8b00924","volume":"18","author":"F Edfors","year":"2019","unstructured":"Edfors F, Forsstr\u00f6m B, Vunk H, Kotol D, Fredolini C, Maddalo G, et al. Screening a resource of recombinant protein fragments for targeted proteomics. J Proteome Res. 2019;18:2706\u20132718.","journal-title":"J Proteome Res"},{"key":"9412_CR40","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1074\/mcp.RA119.001765","volume":"18","author":"A Hober","year":"2019","unstructured":"Hober A, Edfors F, Ryaboshapkina M, Malmqvist J, Rosengren L, Percy AJ, et al. Absolute quantification of apolipoproteins following treatment with omega-3 carboxylic acids and fenofibrate using a high precision stable isotope-labeled recombinant protein fragments based SRM Assay. Mol Cell Proteomics. 2019;18:2433\u201346.","journal-title":"Mol Cell Proteomics"},{"key":"9412_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06642-y","volume":"9","author":"F Edfors","year":"2018","unstructured":"Edfors F, Hober A, Linderb\u00e4ck K, Maddalo G, Azimi A, Sivertsson \u00c3, et al. Enhanced validation of antibodies for research applications. Nat Commun. 2018;9:1\u201310.","journal-title":"Nat Commun"},{"key":"9412_CR42","unstructured":"Mcculloch CE, Searle SR, Neuhaus JM. Generalized Linear Mixed Models. Hoboken: John Wiley & Sons, Ltd; 2008."},{"key":"9412_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: tests in linear mixed effects models. J Stat Softw. 2017;82:1\u201326.","journal-title":"J Stat Softw"},{"key":"9412_CR44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"9412_CR45","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.","journal-title":"Science"},{"key":"9412_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0169-7439(93)80008-6","volume":"20","author":"MA O\u2019Connell","year":"1993","unstructured":"O\u2019Connell MA, Belanger BA, Haaland PD. Calibration and assay development using the four-parameter logistic model. Chemometr Intell Lab Syst. 1993;20:97\u2013114.","journal-title":"Chemometr Intell Lab Syst"},{"key":"9412_CR47","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. R Foundation for Statistical Computing, Vienna. 2014."},{"key":"9412_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14789450.2020.1773806","volume":"17","author":"C Al-Khalili Szigyarto","year":"2020","unstructured":"Al-Khalili Szigyarto C. Duchenne muscular dystrophy: recent advances in protein biomarkers and the clinical application. Expert Rev Proteomics. 2020;17:365\u2013375.","journal-title":"Expert Rev Proteomics"},{"key":"9412_CR49","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1535370217743949","volume":"243","author":"JM Sauer","year":"2018","unstructured":"Sauer JM, Porter AC. Preclinical biomarker qualification. Exp Biol Med (Maywood). 2018;243:222\u2013227.","journal-title":"Exp Biol Med (Maywood)"},{"key":"9412_CR50","doi-asserted-by":"publisher","first-page":"eaal4599","DOI":"10.1126\/scitranslmed.aal4599","volume":"9","author":"C Leptak","year":"2017","unstructured":"Leptak C, Menetski JP, Wagner JA, Aubrecht J, Brady L, Brumfield M, et al. What evidence do we need for biomarker qualification? Sci Transl Med. 2017;9:eaal4599.","journal-title":"Sci Transl Med"},{"key":"9412_CR51","doi-asserted-by":"publisher","first-page":"31727","DOI":"10.1038\/srep31727","volume":"6","author":"Y Hathout","year":"2016","unstructured":"Hathout Y, Conklin LS, Seol H, Gordish-Dressman H, Brown KJ, Morgenroth LP, et al. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Sci Rep. 2016;6:31727.","journal-title":"Sci Rep"},{"key":"9412_CR52","doi-asserted-by":"publisher","first-page":"O111009613","DOI":"10.1074\/mcp.O111.009613","volume":"11","author":"M Zeiler","year":"2012","unstructured":"Zeiler M, Straube WL, Lundberg E, Uhlen M, Mann M. A protein epitope signature tag (PrEST) library allows SILAC-based absolute quantification and multiplexed determination of protein copy numbers in cell lines. Mol Cell Proteomics. 2012;11:O111009613.","journal-title":"Mol Cell Proteomics"},{"key":"9412_CR53","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1002\/pmic.200800203","volume":"8","author":"L Berglund","year":"2008","unstructured":"Berglund L, Bj\u00f6rling E, Jonasson K, Rockberg J, Fagerberg L, Szigyarto CAK, et al. A whole-genome bioinformatics approach to selection of antigens for systematic antibody generation. Proteomics. 2008;8:2832\u20132839.","journal-title":"Proteomics"},{"key":"9412_CR54","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/clinchem\/27.10.1642","volume":"27","author":"BT Doumas","year":"1981","unstructured":"Doumas BT, Bayse DD, Carter RJ, Peters T, Schaffer R. A candidate reference method for determination of total protein in serum. I. Development and validation. Clin Chem. 1981;27:1642\u20131650.","journal-title":"Clin Chem"},{"key":"9412_CR55","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/ac051632c","volume":"78","author":"F Dieterle","year":"2006","unstructured":"Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006;78:4281\u20134290.","journal-title":"Anal Chem"},{"key":"9412_CR56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11306-011-0350-z","volume":"8","author":"SM Kohl","year":"2012","unstructured":"Kohl SM, Klein MS, Hochrein J, Peter \u2022, Oefner J, Spang R, et al. State-of-the art data normalization methods improve NMR-based metabolomic analysis. Metabolomics. 2012;8:146\u2013160.","journal-title":"Metabolomics"},{"key":"9412_CR57","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1093\/clinchem\/20.12.1520","volume":"12","author":"P Winkel","year":"1974","unstructured":"Winkel P, Statland BE, Bokelund H. Factors contributing to Intra-Individual Variation of serum variation of serum constituents in healthy subjects. Clin Chem. 1974;12:1520.","journal-title":"Clin Chem"},{"key":"9412_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/00365510500208332","volume":"65","author":"T Kouri","year":"2005","unstructured":"Kouri T, Siloaho M, Pohjavaara S, Koskinen P, Malminiemi O, Pohja-Nylander P, et al. Pre-analytical factors and measurement uncertainty. Scand J Clin Lab Invest. 2005;65:463\u2013476.","journal-title":"Scand J Clin Lab Invest"},{"key":"9412_CR59","doi-asserted-by":"publisher","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","volume":"9","author":"Y Hathout","year":"2019","unstructured":"Hathout Y, Liang C, Ogundele M, Xu G, Tawalbeh SM, Dang UJ, et al. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy. Sci Rep. 2019;9:12167.","journal-title":"Sci Rep"},{"key":"9412_CR60","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1073\/pnas.1507719112","volume":"112","author":"Y Hathout","year":"2015","unstructured":"Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK, Furlong P, et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2015;112:7153\u20137158.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9412_CR61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0009-8981(99)00261-2","volume":"294","author":"JR Beuerle","year":"2000","unstructured":"Beuerle JR, Azzazy HME, Styba G, Duh SH, Christenson RH. Characteristics of myoglobin, carbonic anhydrase III and the myoglobin\/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients. Clin Chim Acta. 2000;294:115\u2013128.","journal-title":"Clin Chim Acta"},{"key":"9412_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/clinchem\/37.1.36","volume":"37","author":"M Ohta","year":"1991","unstructured":"Ohta M, Itagaki Y, Itoh N, Hayashi K, Nishitani H, Ohta K. Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase. Clin Chem. 1991;37:36\u201339.","journal-title":"Clin Chem"},{"key":"9412_CR63","first-page":"241","volume":"2","author":"PM Burch","year":"2015","unstructured":"Burch PM, Pogoryelova O, Goldstein R, Bennett D, Guglieri M, Straub V, et al. Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. \/ Serum Biomarkers of Muscular Dystrophy. 2015;2:241\u2013255.","journal-title":"\/ Serum Biomarkers of Muscular Dystrophy"},{"key":"9412_CR64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/cvr\/cvw206","volume":"112","author":"J Barallobre-Barreiro","year":"2016","unstructured":"Barallobre-Barreiro J, Lynch M, Yin X, Mayr M. Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix. Cardiovasc Res. 2016;112:626\u2013636.","journal-title":"Cardiovasc Res"},{"key":"9412_CR65","doi-asserted-by":"publisher","first-page":"26504","DOI":"10.1021\/acsomega.0c03206","volume":"5","author":"TD Alayi","year":"2020","unstructured":"Alayi TD, Tawalbeh SM, Ogundele M, Smith HR, Samsel AM, Barbieri ML, et al. tandem mass tag-based serum proteome profiling for biomarker discovery in young Duchenne muscular dystrophy boys. ACS Omega. 2020;5:26504\u201326517.","journal-title":"ACS Omega"},{"key":"9412_CR66","first-page":"e015346","volume":"11","author":"SM Boca","year":"2016","unstructured":"Boca SM, Nishida M, Harris M, Rao S, Cheema AK, Gill K, et al. Discovery of metabolic biomarkers for Duchenne muscular dystrophy within a natural history study. PLoS ONE. 2016;11:e015346.","journal-title":"PLoS ONE"},{"key":"9412_CR67","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1515\/CCLM.2010.179","volume":"48","author":"P Brancaccio","year":"2010","unstructured":"Brancaccio P, Lippi G, Maffulli N. Biochemical markers of muscular damage. Clin Chem Lab Med. 2010;48:757\u2013767.","journal-title":"Clin Chem Lab Med"},{"key":"9412_CR68","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1113\/JP282227","volume":"599","author":"WJ Evans","year":"2021","unstructured":"Evans WJ, Shankaran M, Smith EC, Morris C, Nyangau E, Bizieff A, et al. Profoundly lower muscle mass and rate of contractile protein synthesis in boys with Duchenne muscular dystrophy. J Physiol. 2021;599:1389\u20131396.","journal-title":"J Physiol"},{"key":"9412_CR69","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1177\/0192623316668276","volume":"44","author":"K Kim","year":"2016","unstructured":"Kim K, Chini N, Fairchild DG, Engle SK, Reagan WJ, Summers SD, et al. Evaluation of Cardiac toxicity biomarkers in rats from different Laboratories. Toxicol Pathol. 2016;44:1072\u20131083.","journal-title":"Toxicol Pathol"},{"key":"9412_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.semcdb.2016.09.013","volume":"64","author":"AL Serrano","year":"2017","unstructured":"Serrano AL, Mu\u00f1oz-C\u00e1noves P. Fibrosis development in early-onset muscular dystrophies: mechanisms and translational implications. Semin Cell Dev Biol. 2017;64:181\u2013190.","journal-title":"Semin Cell Dev Biol"},{"key":"9412_CR71","doi-asserted-by":"crossref","unstructured":"Dowling P, Gargan S, Zweyer M, Sabir H, Swandulla D, Ohlendieck K. Proteomic profiling of carbonic anhydrase CA3 in skeletal muscle. 2021;18:1073\u20131086.","DOI":"10.1080\/14789450.2021.2017776"},{"key":"9412_CR72","doi-asserted-by":"crossref","unstructured":"Choi J-O, Yu C-W, Jong NC, Park JR et al. Long-term outcome of 4 korean families with hypertrophic cardiomyopathy caused by 4 different mutations. 2010; 33:430\u2013438.","DOI":"10.1002\/clc.20795"},{"key":"9412_CR73","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00018-012-1248-2","volume":"70","author":"S Duguez","year":"2013","unstructured":"Duguez S, Duddy W, Johnston H, Lain\u00e9 J, Le Bihan MC, Brown KJ, et al. Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion. Cell Mol Life Sci. 2013;70:2159\u20132174.","journal-title":"Cell Mol Life Sci"},{"key":"9412_CR74","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/ATVBAHA.116.308595","volume":"37","author":"J Srvya Kattula","year":"2017","unstructured":"Srvya Kattula J. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2017;37:e13\u201321.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9412_CR75","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gad.465908","volume":"22","author":"B Vidal","year":"2008","unstructured":"Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, et al. Fibrinogen drives dystrophic muscle fibrosis via a TGF\u03b2\/alternative macrophage activation pathway. Genes Dev. 2008;22:1747\u20131752.","journal-title":"Genes Dev"},{"key":"9412_CR76","doi-asserted-by":"publisher","first-page":"13540","DOI":"10.3390\/ijms232113540","volume":"23","author":"JL Romero-Cabrera","year":"2022","unstructured":"Romero-Cabrera JL, Ankeny J, Fern\u00e1ndez-Montero A, Kales SN, Smith DL. A systematic review and meta-analysis of advanced biomarkers for predicting incident cardiovascular disease among asymptomatic middle-aged adults. Int J Mol Sci. 2022;23:13540.","journal-title":"Int J Mol Sci"},{"key":"9412_CR77","doi-asserted-by":"publisher","first-page":"e1700463","DOI":"10.1002\/pmic.201700463","volume":"18","author":"M Frantzi","year":"2018","unstructured":"Frantzi M, Latosinska A, Kontostathi G, Mischak H. Clinical proteomics: closing the gap from discovery to implementation. Proteomics. 2018;18:e1700463.","journal-title":"Proteomics"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-023-09412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-023-09412-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-023-09412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:03:40Z","timestamp":1729566220000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-023-09412-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["9412"],"URL":"https:\/\/doi.org\/10.1186\/s12014-023-09412-1","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the Declaration of Helsinki and approved by the LUMC Commissie Medische Ethiek and the study was approved by Regionala etikpr\u00f6vningsn\u00e4mnden Stockholm, Sweden (ref. 2018\/1859-31\/1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate in the study was obtained from all participants and legal guardians (in the case of children) prior to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no competing interests as defined by BMC or other interests that might be perceived to influence the results and\/or discussion reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}